Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 8/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25753667 | 0.85 | KCNA5 (0.37) | KCNA5TACR3 | |
| SCHEMBL25753673 | 0.85 | WDR5 (0.43) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL18511287 | 0.85 | KCNA5 (0.50) | KCNA5 | |
| SCHEMBL24036985 | 0.85 | KCNA5 (0.47) | KCNA5KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL25623356 | 0.85 | KCNA5 (0.37) | KCNA5TACR3 | |
| SCHEMBL24036979 | 0.85 | WDR5 (0.43) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL25753676 | 0.85 | KCNA5 (0.47) | KCNA5KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL25753692 | 0.84 | EEF2K (0.45) | KMT2AMEN1POLB | |
| SCHEMBL24036809 | 0.84 | EEF2K (0.45) | KMT2AMEN1POLB | |
| SCHEMBL24036741 | 0.83 | KDM4E (0.38) | KCNA5KMT2AMEN1POLBROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431602-B2 | Beta-amino acid derivatives for treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-30 | — | — | US | disclosed |
| EP-2231640-B1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-12-30 | — | — | US | disclosed |
| EP-2231640-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009092432-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | GPR119, GLS, GCKR | KCNA5 953/4885TACR3 1851/4885KMT2A 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.